鉴定ZG16B作为乳腺癌的预后生物标志物。
Identification of ZG16B as a prognostic biomarker in breast cancer.
作者信息
Lu Haotian, Shi Chunying, Liu Xinyu, Liang Chen, Yang Chaochao, Wan Xueqi, Li Ling, Liu Ying
机构信息
School of Basic Medicine, College of Medicine, Qingdao University, Qingdao, 266071, China.
Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, College of Medicine, Qingdao University, Qingdao, 266071, China.
出版信息
Open Med (Wars). 2020 Nov 25;16(1):1-13. doi: 10.1515/med-2021-0004. eCollection 2021.
Zymogen granule protein 16B (ZG16B) has been identified in various cancers, while so far the association between ZG16B and breast cancer hasn't been explored. Our aim is to confirm whether it can serve as a prognostic biomarker in breast cancer. In this study, Oncomine, Cancer Cell Line Encyclopedia (CCLE), Ualcan, and STRING database analyses were conducted to detect the expression level of ZG16B in breast cancer with different types. Kaplan-Meier plotter was used to analyze the prognosis of patients with high or low expression of ZG16B. We found that ZG16B was significantly upregulated in breast cancer. Moreover, ZG16B was closely associated with foregone biomarkers and crucial factors in breast cancer. In the survival analysis, high expression of ZG16B represents a favorable prognosis in patients. Our work demonstrates the latent capacity of ZG16B to be a biomarker for prognosis of breast cancer.
酶原颗粒蛋白16B（ZG16B）已在多种癌症中被鉴定出来，但迄今为止，ZG16B与乳腺癌之间的关联尚未得到探索。我们的目的是确认它是否可作为乳腺癌的预后生物标志物。在本研究中，进行了Oncomine、癌症细胞系百科全书（CCLE）、Ualcan和STRING数据库分析，以检测不同类型乳腺癌中ZG16B的表达水平。使用Kaplan-Meier绘图仪分析ZG16B高表达或低表达患者的预后。我们发现ZG16B在乳腺癌中显著上调。此外，ZG16B与乳腺癌中已有的生物标志物和关键因素密切相关。在生存分析中，ZG16B高表达代表患者预后良好。我们的工作证明了ZG16B作为乳腺癌预后生物标志物的潜在能力。
Zotero 插件